{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:02:02Z","timestamp":1753891322950,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The outcome of AL amyloidosis remains poor, particularly in patients with advanced organ involvement which takes long time to recovery. We conducted an observational study of two patients with AL amyloidosis treated with SDd regimen. Both patients successfully achieved significant hematological and organ responses without severe adverse events, and the time to organ response was remarkably shorter than previously reported. Notably, an over 15% reduction in interventricular septal thickness (IVST) was observed in patient#2 within 6 months. Up to now, SDd therapy has not been previously reported in AL amyloidosis and may be a promising option for these patients.<\/jats:p>","DOI":"10.3389\/fmed.2024.1363805","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T04:58:52Z","timestamp":1714625932000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Light-chain amyloidosis responsive to selinexor in combination with daratumumab and dexamethasone (SDd) therapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiaolu","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimei","family":"Que","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.6004\/jnccn.2022.7077","article-title":"Immunoglobulin light chain amyloidosis: diagnosis and risk assessment","volume":"21","author":"Zanwar","year":"2023","journal-title":"J Natl Compr Canc Netw."},{"key":"B2","doi-asserted-by":"publisher","first-page":"16809","DOI":"10.1038\/s41598-017-16953-7","article-title":"Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity","volume":"7","author":"Oberti","year":"2017","journal-title":"Sci Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1182\/blood-2012-01-407791","article-title":"Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"100581","DOI":"10.1016\/j.blre.2019.05.005","article-title":"Use of novel therapies in the treatment of light chain amyloidosis","volume":"37","author":"Varga","year":"2019","journal-title":"Blood Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","article-title":"A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis","volume":"123","author":"Diomede","year":"2014","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3324\/haematol.11627","article-title":"Efficacy of bortezomib in systemic AL amyloidosis with relapsed\/refractory clonal disease","volume":"93","author":"Wechalekar","year":"2008","journal-title":"Haematologica."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach","volume":"99","author":"Palladini","year":"2014","journal-title":"Haematologica."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","article-title":"The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)","volume":"105","author":"Palladini","year":"2005","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/ejh.13535","article-title":"Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: a multisite study and systematic literature review","volume":"106","author":"Shragai","year":"2021","journal-title":"Eur J Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1182\/bloodadvances.2019000776","article-title":"Organ responses with daratumumab therapy in previously treated AL amyloidosis","volume":"4","author":"Chung","year":"2020","journal-title":"Blood Adv."},{"key":"B17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/jcp.25378","article-title":"XPO1 inhibition preferentially disrupts the 3D nuclear organization of telomeres in tumor cells","volume":"231","author":"Taylor-Kashton","year":"2016","journal-title":"J Cell Physiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/sigtrans.2016.10","article-title":"Inhibiting cancer cell hallmark features through nuclear export inhibition","volume":"1","author":"Sun","year":"2016","journal-title":"Signal Transduct Target Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.3109\/10428194.2013.876630","article-title":"Future directions in the clinical management of amyloid light-chain amyloidosis","volume":"55","author":"Haider","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"B21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14656566.2019.1707184","article-title":"Selinexor for the treatment of multiple myeloma","volume":"21","author":"Podar","year":"2020","journal-title":"Expert Opin Pharmacother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1016\/j.clml.2021.01.001","article-title":"Safety, tolerability, and efficacy of selinexor in a patient with relapsed light chain (AL) amyloidosis","volume":"21","author":"Hughes","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.12669\/pjms.39.1.6667","article-title":"Effect of daratumumab combined with chemotherapy on immune function in patients with relapsed\/refractory multiple myeloma and observation of its clinical efficacy","volume":"39","author":"Zhang","year":"2023","journal-title":"Pak J Med Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41416-021-01608-2","article-title":"Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients","volume":"126","author":"Gasparetto","year":"2022","journal-title":"Br J Cancer."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1363805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T04:58:55Z","timestamp":1714625935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1363805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":25,"alternative-id":["10.3389\/fmed.2024.1363805"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1363805","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"article-number":"1363805"}}